Why the study?
Do dihydropyridines increase cardiovascular events in patients with hypertension and coronary artery disease?
Do dihydropyridines increase cardiovascular events in patients with hypertension and coronary artery disease?
Slow-onset, long-acting dihydropyridine calcium channel blockers appear safe regarding cardiovascular events, whereas short-acting agents have been controversial due to off-label use.
Supports CV safety of long-acting dihydropyridines in hypertension with CAD; leaves open short-acting concerns and requires prospective confirmation.
This review describes aspects of the calcium channel blocker controversy as it relates to hypertensive and coronary artery disease patients. Much of the controversy has occurred because of off-label use of short-acting calcium channel blockers that were never approved or recommended for use in patients with hypertension or acute myocardial infarction. A recent analysis of slow-onset, long-acting calcium channel blockers, which lack large peak-to trough fluctuations in drug levels, did not show a signal suggesting an increase in cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Robert A. Kloner (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: